Drug intelligence / Profile preview

MIV-323

Development stage: Preclinical
Lead developer: Medivir
Modality: Small Molecules

Overview

**MIV-323** is a small molecule fusion inhibitor developed by Medivir AB for the treatment of respiratory syncytial virus (RSV) infection. It targets the RSV F protein, preventing viral fusion with host cell membranes and thereby inhibiting viral entry and replication. Selected as a candidate drug in 2016, it entered non-clinical development, with subsequent involvement noted from Boehringer Ingelheim.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on MIV-323.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIV-323.

Explore the full profile